Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-1 plus oxaliplatin for locally advanced gastric cancer
NCT01946061Phase 2Terminated
- Sponsor
- Yonsei University
- Start
- May 2015
- Primary completion
- Mar 2016
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of tegafur and oxaliplatin in gastric cancer (GC), sponsored by Yonsei University. Primary endpoint: Disease-Free Survival at 3 years. Started May 2015; status: terminated.
02
Drugs
tegafuroxaliplatin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT01946061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01946061.